What we do Syschem (India) Ltd manufactures active pharmaceutical ingredients and intermediates, serving domestic and global pharma markets with high-quality antibiotic compounds. |
Founded in 1,993 |
Market share Strong presence in Indian API market with growing exports to 10+ countries across three continents. |
Problem solved Provides pharmaceutical industry with essential, reliable drug intermediates to ensure availability of critical antibiotics and medicines. |
Top clients or who we serve Pharmaceutical formulation manufacturers; B2B model serving clients like Medico Remedies, Kopran, and Milan Laboratories. |
Key management Ranjan Jain (Managing Director), Suninder Veer Singh (Whole-Time Director), Sanjeev Agrawal (Chief Financial Officer) |
Our journey and innovations Founded in 1993 as pesticide manufacturer; transitioned to pharmaceutical APIs by 2017; expanded capacity, diversified products, and modernized manufacturing. |
Where we operate Primarily India with exports to multiple international markets across three continents. |
Top products or what we offer APIs and intermediates including Amoxicillin, Ampicillin, Cephalexin, Cephadroxil, Flucloxacillin, Cloxacillin among others. |
Top brands No specific consumer-facing brands; flagship APIs such as Amoxicillin and 7-ADCA drive revenues and market position. |
Raw materials needed Chemical precursors for antibiotic synthesis including organic solvents and reagents sourced from chemical suppliers. |
Raw materials supplier Not specified; likely various chemical manufacturers and distributors supporting API production. |
Recurring vs cyclical contribution Revenue largely recurring from consistent API supply contracts, though subject to pharma market demand cycles. |
Our industry position Recognized domestic API manufacturer with growing export footprint; competitive in antibiotic intermediates sector. |
Financial highlights FY 2024-25 revenue Rs. 386.23 cr with net profit Rs. 0.46 cr; 65% revenue growth year-on-year noted in recent quarters. |
Geographical revenue split Domestic sales dominate with growing exports to over 10 countries; exports accounted for approximately 30% of sales. |
Order book - |
Whats driving growth Capacity expansion, increased production, strong export demand, and broadening API product portfolio. |
Our future plans Enhance manufacturing capacity to 8000 TPA; focus on R&D and expanding product range in pharmaceuticals. |
Our green promise Implementing sustainable manufacturing, energy efficiency, waste management, and green technologies. |
Our people and values 115 employees fostering culture of innovation, safety, diversity, and continuous learning. |
Key challenges ahead Rising production costs, regulatory compliance, currency fluctuations, and maintaining profitability amid competition. |
Interesting facts Shifted from pesticides to pharmaceuticals successfully; achieved 164% revenue growth in nine months FY 2025-26. |
Risks and strategy Mitigates currency and market risks via hedging; focuses on quality and compliance to sustain growth. |
